ghp June 2015

ghp June 2015 | 7 ClinicAll Equips an 81-Bed Clinic Another clinic is taking a groundbreaking step towards the digital hospital of the future. In connection with ex- tensive modernization measures, the Grupo Policlínico Quirurgico in Palma de Majorca is equipping its clinic with state-of-the-art technology. It stands to reason that the Group decided to install the innovative Clini- cAll System, thereby achieving two goals at the same time. In addition to standard infotainment services for patients, ClinicAll also offers significant advan- tages that are crucial to future-proofing hospitals. In addition to standard patient infotainment services, i.e. optimizing processes and cutting costs by means of intelligent digital networks. Thanks to ClinicAll, the Majorcan hospital will be able to incorporate digital medical records into the system, allowing the medical staff to access patient data directly from the patient’s bedside terminal. Thus, in- ternal procedures can be synchronized and controlled more efficiently while optimizing medical care, treat- ment and support. The Grupo Policlínico Quirurgico is so enthusiastic about the ClinicAll System that it immediately concluded an operator agreement with a 10-year term. About 81 beds will be equipped with state-of-the-art mobile and stationary ClinicAll bedside terminals. As the renovation of the clinic continues until December 2015, the installation is expected to be completed by spring 2016. In the near future, patients will therefore be able to enjoy comprehensive communication and infotainment services, including IPTV, Internet via a full web browser, video on demand (VoD), VoIP telephony and access to current news, weather forecasts, online games, clinic information and much more. Thanks to the incorporation of the HIS patient health record that will be implemented as soon as the first installation phase is completed, the medical staff will also benefit promptly from the efficiency of the state-of-the-art ClinicAll solution. news Kineticos Expands Biopharma- ceutical Practice Leadership Team with Two Senior Executive Appointments Kineticos, a specialised management con- sulting firm serving the life sciences industry have recently announced the expansion of their Biopharmaceutical practice leadership team with the additions of Dee Parson Grange, Senior Vice President, and Mark Osterman, Senior Vice President. Both executives will report to James Forte, Managing Director of the Biopharmaceutical practice at Kineticos. Dee Parson Grange joins Kineticos as a sea- soned executive with more than 25 years of experience achieving strategic and operational business goals for both large pharmaceuti- cal and private biotech companies. Prior to Kineticos, Ms. Parson Grange served in various cross-functional leadership roles at Bayer Pharmaceutical, Bayer Biologic Products (now part of Grifols), and Biolex Therapeutics. In ad- dition, she has provided consulting services to global biopharmaceutical companies targeting rare diseases, biosimilars, biobetters, and novel therapeutic proteins. She holds a BS in Biology from Graceland University and a global execu- tive MBA from the Fuqua School of Business at Duke University. Mark Osterman also has over 25 years of ex- perience in the biopharmaceutical industry. He started his career with 11 years at GlaxoSmith- Kline with roles of increasing responsibility in sales, clinical, and marketing before moving to Johnson & Johnson. At J&J, he was Vice President of the Johnson & Johnson Develop- ment Corporation and launched their stem cell internal venture. He also was responsible for the cardiovascular, pulmonary, metabolic, and mimetibody therapeutic areas in the Global Biologic Strategic Marketing group before being recruited to Discovery Labs. Mr. Osterman was Senior Vice President and responsible for com- mercial operations and business development at Discovery Labs before serving as Vice Pres- ident of Global Marketing at Solstice Neuro- sciences. Immediately prior to joining Kineticos, he founded the Osterman Strategy Group, a boutique management consulting firm, where he worked with large and emerging biopharma- ceutical companies as well as medical device companies to help solve their most challenging business issues. Mr. Osterman earned a dual BA in Business Management and Economics from North Carolina State University. “Dee and Mark add extensive cross-functional experience to the practice along with an im- pressive track record of bringing new biophar- maceutical products to market across various therapeutic areas and geographies,” stated Mr. Forte. “Their expertise adds depth to our exist- ing consulting capabilities and credibility to our practice as an increasing number of biopharma clients depend on our team to guide their path to market,” he continued. Appointments